Purdue Pharma said on Friday that it has ceased operations and concluded its bankruptcy, re-emerging as a nonprofit focused on treating ‌opioid addiction, overseen by a new board with government and ...

Purdue Pharma secured court approval for a $125 million settlement with McKinsey & Co. to resolve claims related to the firm’s advisory role in marketing the drugmaker’s opioids.

OxyContin maker Purdue Pharma is set to dissolve and be replaced with a new company operating in the public interest under the settlement of thousands of lawsuits that goes into effect Friday. It’s ...

Type to search articles, cases, and authors. Press ↵ to view all results. The bankruptcy code does not authorize a release and injunction that, as part of a plan of reorganization under Chapter 11, ...

May 1 marks the first payment of billions to try to address ongoing harms from the overdose crisis.

Justin Winerman of BCLP explains that nonconsensual third-party releases remain available under Chapter 15, despite the ...

Newark, New Jersey - A federal judge on Tuesday criminally sentenced OxyContin-maker Purdue Pharma over its role in the opioid crisis, ahead of upcoming bankruptcy proceedings and its dissolution.

Days before Purdue Pharma’s opioid settlement payouts are set to begin, more than 40% of claims have been rejected under tightened documentation rules. The revised $7.4 billion bankruptcy plan ...

Nearly 140,000 people filed claims against the company for the harm they said its drugs caused. Fewer than half of them will get any compensation.